This enables multiple rounds of cellular engineering to produce master cell banks of modified cells that can be expanded and differentiated into immune
effector cells to supply vast amounts of allogeneic, homogeneous therapeutic products.
T follicular helper cells express a distinctive transcriptional profile, reflecting their role as non-Th1/Th2
effector cells that provide help for B cells.
Effector cells. VSV-N peptide-specific CTLs were maintained in vitro by weekly stimulation with the target VSV-N peptide, p52-59.
Regulatory T cells, expressing fork-head box P3T (FOXP3), suppress
effector cells and maintain immune homeostasis and tolerance in various autoimmune disease models, but their role in myocarditis is still debatable [38-41].
Beyond the multiple cell types (inflammatory cells, epithelial cells, fibrogenic
effector cells, endothelial cells, and others) involved in the fibrogenic response, three cellular signal transduction pathways play leading roles in the process of fibrosis: transforming growth factor-beta (TGF-[sz]), mitogen-activated protein kinases (MAPKs) and integrins.[sup][3]
This extends beyond characterization of the standard FcyRIIIa binding and
effector cell cytotoxicity responses to include applications designed to test for differences across FcyRIIIa allotypes that have been shown to play a role in mAb therapeutic efficacy.
Literature shared positive prediction of sting reactivity through allergy specific activity (the allergen-specific IgE to total IgE ratio; sIgE/T-IgE analysis) involving extensive
effector cell activation along with allergen-specific IgE antibody's concentration, affinity (tightness of binding), clonality (epitope specificity) observations.[sup][9]
AK002 is unique in that it targets both eosinophils and mast cells, two major
effector cell types that cause disease-related tissue damage.
The analysis demonstrated a CD8+ T
effector cell response in patients who achieved a clinical benefit, suggesting a therapy-driven restoration of the anti-tumor immune response in patients who had become refractory to prior checkpoint inhibitor treatment.
The activity of numerous therapeutic antibodies is mediated in part by immune-mediated
effector cell function following binding of the variable regions of the antibody to a specific antigen on the surface of target cells and the interaction of the Fc moiety of the antibody with an Fc receptor on an immune
effector cell [1].
This trial evaluated a 1st-generation GD2-specific CAR in children with relapsing/refractory neuroblastoma and compared the safety, persistence, and antitumor efficacy of two
effector cell populations: activated T cells (ATC) and Epstein-Barr virus specific cytotoxic lymphocytes (EBV-CTLs) [120].
To determine whether
effector cell activation is sufficient to mediate tumor cell killing, we compared enavatuzumab-induced
effector cell activation and tumor cell killing across a range of effector: target ratios (E:T).
CAR technology activates T cell and Natural Killer cell functionality within one
effector cell population, sourced from healthy donor or cord blood.
